Core Viewpoint - The company is transitioning towards the biomanufacturing industry, with the S1 production line already operational for a quarter and the S2 production line currently in testing phase [1] Group 1: Investment and Production Capacity - The total investment for the biodirected synthesis project is approximately 587.04 million yuan [1] - The S1 production line is gradually releasing capacity in response to market demand, with good sales performance [1] - The S2 production line is progressing according to the engineering schedule, with plans for production to commence in 2026 [1]